NanoScientium to support nanomedicine projects in UK

Published: 17-Feb-2014

Will provide analysis of technical, clinical and market information for those investing in nanomedicines, nanosimilars or medical devices


The UK's Nanotechnology Knowledge Transfer Network (NanoKTN) has announced a new start-up company called NanoScientium, which will provide analysis of technical, clinical and market information for those investing in nanomedicines, nanosimilars or medical devices.

The organisation has been set up following a NanoKTN NanoPharm focus group meeting held last year at the Stevenage Bioscience Catalyst.

The meeting brought together pharma industry experts, regulators and academics, to scope out a plan that would kickstart an increase in the number of nanomedicine projects in the UK.

'One of the key aspects that arose from the meeting was that there is a lot of information and data openly available in this space, thus significant value would be brought to this community if this information could be harnessed and translated to specific company needs,' said Felicity Sartain, Founder and Director of NanoScientium. 'Consequently, with support provided by both Stevenage Bioscience Catalyst and the NanoKTN, we set up NanoScientium to provide comprehensive analysis of technical, clinical and market information for those investing capital or resources into nanomedicines, nanosimilars or medical devices.'

Martino Picardo, CEO of Stevenage Bioscience Catalyst, said: 'Both SBC and NanoScientium share a common interest and ambition to explore opportunities in the big data and convergent medical technologies area; we see each other as excellent partners.'

NanoScientium provides assessments of nanotechnologies to determine their potential as nanomedicines, which will look at route to market strategies, illustrate technology or company positions in the competitive landscape, and put a values on their markets.

Alec Reader, Director at the NanoKTN, added, 'The global nanomedicine market is anticipated to grow to US$130.9bn by 2016 and we believe that NanoScientium’s provision of evidence-based assessments of nanomedicines by senior experts in the field, will have a positive impact on the way that investors, and the public in general, look at these new disruptive technologies. We look forward to seeing the future success of NanoScientium and are delighted to have played a part in its foundation.'

You may also like